Non-gestational ovarian choriocarcinoma

Summary

Non-gestational ovarian choriocarcinoma (MONDO:0004322) is a disease. A subtype of ovarian primitive germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-gestational ovarian choriocarcinoma
Mondo ID	MONDO:0004322
DOID	DOID:7665
NCIT	C39991
UMLS	C1518355
MedGen	274798
GARD	0023934
Is cancer (heuristic)	no

Data availability: 1 cell line.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › malignant germ cell tumor of ovary › ovarian primitive germ cell tumor › non-gestational ovarian choriocarcinoma

Related subtypes (3): dysgerminoma of ovary, ovarian mixed germ cell neoplasm, malignant non-dysgerminomatous germ cell tumor of ovary

Subtypes (1): childhood choriocarcinoma of the ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.